SCHEMBL6891876

SCHEMBL6891876

N#Cc1ccc(CN2CCN(S(=O)(=O)c3cccc(Cn4ccnc4)c3)CC2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 11/20 0.53
CYP17A1 P05093 6/20 0.53
CYP21A2 P08686 6/20 0.53
CYP19A1 P11511 6/20 0.51
CYP11B2 P19099 3/20 0.51
FNTA P49354 3/20 0.42
FNTB P49356 3/20 0.42
CYP3A4 P08684 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41
PGGT1B P53609 2/20 0.41
CYP7A1 P22680 1/20 0.41
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7048649 0.84 F10 (0.49) CYP11B1CYP17A1CYP21A2CYP19A1CYP11B2
SCHEMBL6895122 0.83 USP2 (0.47) FNTAFNTBCYP3A4MEN1USP2
SCHEMBL6895006 0.77 PKM (0.48) CYP3A4MEN1USP2ALDH1A1MAPK1
SCHEMBL6895154 0.76 F10 (0.49) FNTAFNTBKMT2AF10
SCHEMBL6894382 0.75 USP2 (0.47) FNTAFNTBCYP3A4MEN1USP2
Hydrochloric Acid SCHEMBL6897024 0.75 F10 (0.52) CYP19A1CYP3A4F10
SCHEMBL6895642 0.73 F10 (0.50) ALDH1A1MAPK1SMN1; SMN2F10
Hydrochloric Acid SCHEMBL6891758 0.73 CYP19A1 (0.43) CYP11B1CYP17A1CYP21A2CYP19A1
Hydrochloric Acid SCHEMBL6891778 0.73 CYP19A1 (0.43) CYP11B1CYP17A1CYP21A2CYP19A1
SCHEMBL6892965 0.72 USP2 (0.47) FNTAFNTBCYP3A4MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 US disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 US disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 CYP11B1 893/4885CYP17A1 575/4885CYP21A2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.